

Zydus Cadila's anti-diabetic drug gets USFDA marketing nod

14 July 2017 | News

The company has received tentative approval to market sitagliptin and metformin hydrochloride



The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market sitagliptin and metformin hydrochloride in the strength of 50mg/500 mg and 50mg/1000 mg

The approved drug is a fixed dose combination of two anti-diabetic drugs indicated for type II diabetes and will be produced at the group's formulation manufacturing facility at the pharma SEZ in Ahmedabad.

The group now has nearly 120 approvals from the USFDA and so far filed 300 abbreviated new drug applications (ANDAs), Cadila Healthcare said.